2. Membrane Transporter/Ion Channel Neuronal Signaling Immunology/Inflammation
  3. Calcium Channel SOD
  4. Levamlodipine besylate

Levamlodipine besylate  (Synonyms: (S)-Amlodipine besylate; Levoamlodipine besylate)

Cat. No.: HY-14744A Purity: 99.76%
SDS COA Handling Instructions

Molarity Calculator

Levamlodipine besylate ((S)-Amlodipine besylate) is an orally active calcium channel blocker with antioxidant and vasodilatory properties. Levamlodipine besylate can reduce serum malondialdehyde (MDA) levels, increase superoxide dismutase (SOD) activity, and improve oxidative stress. Levamlodipine besylate can be used for research on vascular dementia, hypertension, and cerebrovascular diseases.

For research use only. We do not sell to patients.

Levamlodipine besylate Chemical Structure

Levamlodipine besylate Chemical Structure

CAS No. : 150566-71-5

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 50 In-stock
Solution
10 mM * 1 mL in DMSO USD 50 In-stock
Solid
5 mg USD 32 In-stock
10 mg USD 45 In-stock
25 mg USD 80 In-stock
50 mg USD 112 In-stock
100 mg USD 155 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Levamlodipine besylate:

Levamlodipine besylate Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Levamlodipine besylate

View All Calcium Channel Isoform Specific Products:

View All Isoforms
N-type calcium channel L-type calcium channel P/Q-type calcium channel T-type calcium channel Calcium Channel

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Levamlodipine besylate ((S)-Amlodipine besylate) is an orally active calcium channel blocker with antioxidant and vasodilatory properties. Levamlodipine besylate can reduce serum malondialdehyde (MDA) levels, increase superoxide dismutase (SOD) activity, and improve oxidative stress. Levamlodipine besylate can be used for research on vascular dementia, hypertension, and cerebrovascular diseases[1][2][3][4].
IC50 & Target

Calcium channel[1].
In Vitro

Levamlodipine besylate (5-50 μM, 2 h) can prevent cortical neuronal cell death induced by oxidative stress[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Levamlodipine besylate Related Antibodies

Cell Viability Assay[4].

Cell Line: Neuronal cell
Concentration: 0-50 μM
Incubation Time: 2 h
Result: Inhibited cell viability at concentrations greater than 5 μM.
In Vivo

Levamlodipine besylate (0.1, 0.5 mg/kg, once daily; 8 weeks; p.o.) can restore hippocampal Ca2+/CaM dependent protein kinase II (CaMKII) and alleviate hippocampal dependent spatial cognitive impairment in vascular dementia mice[1].
Levamlodipine besylate (1 mg/kg, once daily; 16 weeks; p.o.) can lower blood pressure and protect organs in spontaneously hypertensive rats[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Spontaneously hypertensive rats (SHR)[3].
Dosage: 1 mg/kg
Administration: Oral gavage (p.o.); once daily; 16 weeks
Result: Reduced systolic blood pressure (SBP) and diastolic blood pressure (DBP), reduced heart and aortic hypertrophy, increased kidney weight to prevent kidney atrophy.
Animal Model: VaD mice model of right unilateral common carotid arteries occlusion (rUCCAO)[1].
Dosage: 0.1, 0.5 mg/kg
Administration: Oral gavage (p.o.); once daily; 8 weeks
Result: Recovered phosphorylated CaMKII (Thr286) levels in the hippocampus and improved cognitive impairment in mice.
Clinical Trial
Molecular Weight

567.05

Formula

C26H31ClN2O8S
CAS No.
Appearance

Solid

Color

White to light yellow

SMILES

O=C(C1=C(COCCN)NC(C)=C(C(OC)=O)[C@@H]1C2=CC=CC=C2Cl)OCC.OS(C3=CC=CC=C3)(=O)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

-20°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility
In Vitro: 

DMSO : ≥ 150 mg/mL (264.53 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : ≥ 3.33 mg/mL (5.87 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.7635 mL 8.8176 mL 17.6351 mL
5 mM 0.3527 mL 1.7635 mL 3.5270 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (4.41 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (4.41 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.76%

SDS (252 KB)

COA (258 KB) HNMR (208 KB) RP-HPLC (110 KB) LCMS (120 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O / DMSO 1 mM 1.7635 mL 8.8176 mL 17.6351 mL 44.0878 mL
5 mM 0.3527 mL 1.7635 mL 3.5270 mL 8.8176 mL
DMSO 10 mM 0.1764 mL 0.8818 mL 1.7635 mL 4.4088 mL
15 mM 0.1176 mL 0.5878 mL 1.1757 mL 2.9392 mL
20 mM 0.0882 mL 0.4409 mL 0.8818 mL 2.2044 mL
25 mM 0.0705 mL 0.3527 mL 0.7054 mL 1.7635 mL
30 mM 0.0588 mL 0.2939 mL 0.5878 mL 1.4696 mL
40 mM 0.0441 mL 0.2204 mL 0.4409 mL 1.1022 mL
50 mM 0.0353 mL 0.1764 mL 0.3527 mL 0.8818 mL
60 mM 0.0294 mL 0.1470 mL 0.2939 mL 0.7348 mL
80 mM 0.0220 mL 0.1102 mL 0.2204 mL 0.5511 mL
100 mM 0.0176 mL 0.0882 mL 0.1764 mL 0.4409 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Levamlodipine besylate Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Levamlodipine besylate150566-71-5(S)-Amlodipine besylateLevoamlodipine besylateCalcium ChannelSODCa2+ channelsCa channelsSuperoxide Dismutasecalcium channelvasodilationhypertensioncerebrovascularInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Levamlodipine besylate
Cat. No.:
HY-14744A
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.